RET and thyroid gland carcinoma: The RET inhibitor selpercatinib has recently been approved for lung and thyroid cancers harbouring RET gene mutations or fusions [10], and pralsetinib has been recently reported to be a new, well-tolerated, promising treatment option for patients with RET fusion-positive LACs [28].